Kymera Therapeutics Inc

NASDAQ:KYMR   10:57:07 AM EDT
20.40
+0.27 (+1.34%)
Products

Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333, A First-In-Class, Investigational STAT3 Degrader

Published: 06/01/2022 13:02 GMT
Kymera Therapeutics Inc (KYMR) - Kymera Therapeutics Receives FDA Orphan Drug Designation for Kt-333, a First-in-class, Investigational Stat3 Degrader for the Treatment of Peripheral T-cell Lymphoma.